Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.46 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HTR7 | P34969 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7706497 | 0.91 | OPRL1 (0.54) | POLBOPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL7706380 | 0.89 | DRD4 (0.50) | OPRL1OPRM1OPRD1OPRK1ALDH1A1 | |
| SCHEMBL16876782 | 0.88 | CHRNA7 (0.47) | LMNAOPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL16876781 | 0.88 | OPRL1 (0.46) | OPRL1OPRM1OPRD1OPRK1SIGMAR1 | |
| SCHEMBL5556020 | 0.88 | DRD2 (0.47) | LMNAOPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL8893354 | 0.87 | SIGMAR1 (0.53) | LMNAPOLBALDH1A1NPSR1MAPT | |
| SCHEMBL21634309 | 0.87 | CCR5 (0.45) | LMNAOPRL1OPRM1OPRD1OPRK1 | |
| SCHEMBL7703855 | 0.87 | MCHR1 (0.47) | LMNAPOLBOPRL1OPRM1OPRD1 | |
| SCHEMBL16876851 | 0.85 | RORC (0.42) | OPRL1OPRM1OPRD1OPRK1CXCR3 | |
| SCHEMBL16876761 | 0.84 | OPRL1 (0.43) | LMNAPOLBOPRL1OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3829579-B1 | 1,3,8-TRIAZASPIRO COMPOUNDS AND THEIR USE AS MEDICAMENTS FOR THE TREATMENT OF REPERFUSION INJURY | MARIA CECILIA HOSPITAL S P A (IT) | 2023-08-02 | — | — | EP | disclosed |
| WO-2020021378-A1 | 1,3,8-TRIAZASPIRO COMPOUNDS AND THEIR USE AS MEDICAMENTS FOR THE TREATMENT OF REPERFUSION INJURY | MARIA CECILIA HOSPITAL S.P.A. (IT) | 2020-01-30 | — | — | WO | disclosed |
| US-9951046-B2 | TRPA1 modulators | ALGOMEDIX, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20170001983-A1 | TRPA1 MODULATORS | ALGOMEDIX, INC. | 2017-01-05 | — | — | US | disclosed |
| EP-0921125-B1 | 1,3,8-Triazaspiro[4,5]decan-4-on derivatives | HOFFMANN LA ROCHE (CH) | 2002-01-30 | — | — | EP | disclosed |
| US-6043366-A | USEFUL IN TREATING DISORDERS INVOLVING THE ORPHANIN FQ(A SEVENTEEN AMINO ACID LONG PEPTIDE) RECEPTOR. | HOFFMAN-LA ROCHE INC. (US) | 2000-03-28 | — | — | US | disclosed |
| EP-0921125-A1 | 1,3,8-Triaza-spiro 4,5 decan-4-on derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001983-A1 | TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | LMNA 3839/4885POLB 4513/4885OPRL1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.